Senseonics Holdings, Inc. to Participate in the Stifel 2025 Healthcare Conference
Rhea-AI Summary
Senseonics (NYSE American: SENS) will participate in the Stifel 2025 Healthcare Conference in New York on Wednesday, November 12, 2025. The company will take part in a fireside chat and hold one-on-one meetings at 4:40 PM ET. Interested parties may watch a live and recorded webcast via the company’s Investor Relations website at www.senseonics.com. The presentation provides management access for investors and analysts to discuss the company’s long-term implantable CGM systems and strategic outlook.
Positive
- None.
Negative
- None.
News Market Reaction 11 Alerts
On the day this news was published, SENS gained 5.32%, reflecting a notable positive market reaction. Argus tracked a peak move of +6.2% during that session. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $14M to the company's valuation, bringing the market cap to $279M at that time.
Data tracked by StockTitan Argus on the day of publication.
GERMANTOWN, Md., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Stifel 2025 Healthcare Conference, being held in New York, NY.
2025 Stifel Healthcare Conference
Format: Fireside chat and one-on-one meetings
Date: Wednesday, November 12, 2025
Time: 4:40 pm ET
Webcast: Click here
Interested parties may access a live and recorded webcast of the presentation on the “Investor Relations” section of the company’s website at www.senseonics.com.
About Senseonics
Senseonics Holdings, Inc. (“Senseonics”) is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.
Senseonics Investor Contact
Jeremy Feffer
LifeSci Advisors
investors@senseonics.com
FAQ
When will Senseonics (SENS) present at the Stifel 2025 Healthcare Conference?
How can investors watch the Senseonics (SENS) Stifel 2025 presentation?
What format will Senseonics (SENS) use at the Stifel 2025 Healthcare Conference?
What topics will Senseonics (SENS) likely cover at the Stifel 2025 Healthcare Conference?
Where is the Stifel 2025 Healthcare Conference being held for Senseonics (SENS)?
